Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference
June 26 2023 - 4:38PM
Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage
biopharmaceutical company focused on developing tumor infiltrating
lymphocyte, or TIL, therapies for the treatment of patients with
cancer, today reported an oral presentation at the British Society
for Gene and Cell Therapy Annual Conference, demonstrating that its
proprietary CoStimulatory Antigen Receptor (CoStAR) platform
enhances activity of TILs against autologous tumor.
The presentation highlighted CoStAR’s unique mechanism of action
which results in greatly enhanced activity of TILs when activation
occurs through both the native TCR and engineered CoStAR receptors.
Additionally, novel data demonstrated that Instil’s FRα-CoStAR
enhances activity of TILs against autologous tumors with varied
expression of FRα including ovarian, renal, and non-small cell lung
cancer tumors. The robust activity of NSCLC, ovarian, and renal
carcinoma CoStAR-TILs against autologous tumor exceeded that of
genetically unmodified melanoma TILs, as measured by secretion of
IFNγ.
“The finding that CoStAR can enhance the anti-tumor reactivity
of TILs in challenging tumor types such as non-small cell lung
cancer even beyond that seen with melanoma TILs is compelling,”
said Robert Hawkins, MBBS PhD, Head of Research and Development at
Instil Bio. “These preclinical data continue to support our
excitement around the anticipated resumption of the clinical study
of ITIL-306 in patients with advanced cancers which express
FRα.”
About Instil Bio
Instil Bio, Inc. (Nasdaq: TIL) is a clinical-stage
biopharmaceutical company focused on developing TIL therapies for
the treatment of patients with cancer. Instil has assembled an
accomplished management team with a successful track record in the
research, development and manufacture of cell therapies. Using its
proprietary and optimized manufacturing processes at its in-house
manufacturing facilities, Instil is developing a novel class of
genetically engineered TIL therapies using its Co-Stimulatory
Antigen Receptor, or CoStAR™, platform, including ITIL-306, a
next-generation, genetically-engineered TIL therapy using the
CoStAR platform, for multiple solid tumors. For more information
visit www.instilbio.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “anticipates,” “believes,” “expects,” “future,”
“intends,” “plans,” “potential,” “projects,” and “will” or similar
expressions are intended to identify forward-looking statements.
Forward-looking statements include statements concerning or
implying the therapeutic potential of our product candidates, our
research, development and regulatory plans for our product
candidates, including our expectations of CTA clearance from the
MHRA, the timing of our ongoing and potential future clinical
trials and studies and the availability and presentation of data
therefrom, including our expectations concerning the initiation of,
and timing of updates on, our ITIL-306 clinical trial in the United
Kingdom, the potential for us to make submissions concerning, and
for our product candidates to receive, regulatory approval from the
FDA, MHRA or equivalent foreign regulatory agencies and whether, if
approved, these product candidates will be successfully distributed
and marketed, the anticipated sale or lease of our Tarzana,
California manufacturing facility, our cash runway and quarterly
cash burn, and other statements that are not historical fact.
Forward-looking statements are based on management's current
expectations and are subject to various risks and uncertainties
that could cause actual results to differ materially and adversely
from those expressed or implied by such forward-looking statements,
including risks and uncertainties associated with the costly and
time-consuming cell therapy product development process and the
uncertainty of clinical success, including risks related to failure
or delays in successfully initiating, enrolling, reporting data
from or completing clinical studies, as well as the risks that
results obtained in clinical trials to date may not be indicative
of results obtained in ongoing or future trials and that Instil’s
product candidates may otherwise not be effective treatments in
their planned indications; macroeconomic conditions, including as a
result of the ongoing COVID-19 pandemic, the ongoing conflict
between Russia and Ukraine, bank failures and other factors, which
could materially and adversely affect Instil’s business and
operations, including Instil's ability to timely initiate, enroll
and complete its ongoing and future clinical trials; the
time-consuming and uncertain regulatory approval process; risks
inherent in manufacturing and testing of cell therapy products; the
sufficiency of Instil’s cash resources, and other risks and
uncertainties affecting Instil and its development programs,
including those discussed in the section titled “Risk Factors” in
our Annual Report on Form 10-K for the year ended December 31,
2022 available on the SEC’s website at www.sec.gov, and in our
Quarterly Report on Form 10-Q for the quarter ended March 31,
2023 to be filed with the SEC. Additional information will be made
available in other filings that we make from time to time with the
SEC. Accordingly, these forward-looking statements do not
constitute guarantees of future performance, and you are cautioned
not to place undue reliance on these forward-looking statements.
These forward-looking statements speak only as the date hereof, and
we disclaim any obligation to update these statements except as may
be required by law.
Contacts:
Investor Relations
1-972-499-3350 investorrelations@instilbio.com
www.instilbio.com
Instill Bio (NASDAQ:TIL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Instill Bio (NASDAQ:TIL)
Historical Stock Chart
From Apr 2023 to Apr 2024